A friend of ours on the Maine island where we spent our vacation told us that her husband’s surgery had been cancelled at the last minute because the hospital in Portland was swamped with COVID cases, and all elective surgery was cancelled. This notification came at the last possible minute, as they were getting ready […]
Articles
Yesterday I spent some time on a pitch for a “Diamond in the Rough” stock from Jim Woods and promised to follow up… so that’s the plan this afternoon. The bigger theme of the ad was that Woods has a list of five “Guardian Angel” stocks that will help you survive pandemics and recessions… and […]
The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently featured the phrase “for the duration” – as in great numbers of combat fatalities would continue to be reported for the duration, […]
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and former journalist Suzanne Sena that Money Morning brings in to pitch their “super vaccine” idea… which doesn’t mean anything about the stock, of […]
During these crazy market moves, a lot of us are keeping in the back of our mind a notion along the lines of, “hey, this might be the chance to buy something cheap… but it better be really, really good!” And for many of us, that means our minds drift to “blue chip” type stocks […]
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports” on the stocks he thinks will make you a lot of money as we fight COVID-19… and, of course, […]
Don’t look to Doc Gumshoe to keep you up to the minute on the spread of the Wuhan coronavirus. The figures I’m quoting below are as of mid-day today, February 18th. These will have changed by the time you see this piece, and they may be unreliable in the first place. But, […]
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
Way back in April 2018, the World Health Organization issued its Thirteenth General Programme of Work, which attracted a certain amount of notice at the time, but was certainly not treated as front-page news. The GPW 13, as WHO called it, was centered on three ambitious targets – worthy, but in the view of […]
“For such a beastly month as February, 28 days as a rule are plenty,” said the Pirate King. But you would be surprised at the number of interesting snippets of news in the health-care realm that landed in my inbox during this short month. I’ll lead off with one that gave me a particular kick. […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He’s agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see his past articles and most recent comments here.] The death of Mr. Chiang, who was always kind, has never set well […]
Alzheimer’s Wrap-Up[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes non-investment articles for us about medical and health topics a couple times a month. He is a medical writer, not a doctor, and his words and thoughts are his own.] Just possibly a tiny few of the Gumshoe faithful may remember that advertising […]
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
[ed. note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer who shares his thoughts with us a couple times a month. He is not a doctor, and his articles are not typically focused on investment ideas] This post will neither spook you nor cheer you up. In adding Doc […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
Today the pitch that’s been catching my eye is from Mitchell Clark for his Biotech Breakthrough Stock Report — we haven’t covered this newsletter before, but we have certainly covered teaser spiels from Mitchell Clark’s wide variety of Lombardi-published newsletters in the past (before he was a biotech expert this week, he was a bible […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
[Ed. Note: Here is the latest from Dr. KSS, who writes about health, medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and ideas are his own.] Dedicated to Cynthia Chew Choon Hoon (1959-2013). In pace requiescat. Imagine a day down the hallway of the future. You’re […]
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]
[Ed. Note: Here is the latest contribution from Dr. KSS, who writes for the Irregulars about medicine and biomedical stocks. As always, he has agreed to our trading restrictions and his words and thoughts are his own.] The Belle of the Everglades How To Profit From The Cure First of Two Parts Of the many […]
[Ed. Note: Dr. KSS, formerly knowns as karmaswimswami on our discussion threads, is here again to talk to the Irregulars about health and medicine and biotech investing ideas. As with all of our guest contributors, he has agreed to our trading restrictions and we have not reviewed, approved or screened his stocks or ideas, and […]
[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice. As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]
[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
It isn’t necessarily easy to make money from broad demographic shifts, since they take time and are difficult to predict in a detailed way — but the move of the baby boom generation through the various stages of their life to now has had a momentous impact on almost every part of American life, from […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
Today’s tease didn’t come to me directly and I haven’t seen the original ad or letter where it appeared, but this excerpt was forwarded by a large number of folks who appear to have some interest in a good ‘ol blue chip-type investment. The tease must have been in some kind of subscribers-only letter for […]
I’ve been getting lots of questions about this secret toll-free phone number this week, so I thought I should try to take a look for you today. Apparently it’s all about some way to boost your dividend by calling a special phone number — which can’t help but conjure up a mental image of vast […]
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
3m will become a major player in non fixative materials, as will jnj...
@drbonz So good to hear from you. My average cost on $CWBR is $3.13, so I'm definitely underwater. You must have ...
I watch alot of youtube penny stock videos as well. Some have a big following. Most have private discord servers where I...
I wouldn't count out the JNJ vaccine from being the big winner. Their main candidate has shown to protect monkeys expos...
Egads man, maybe I need THIS drug - I mean I went walking - old guys have time for that you know! I thought I was going ...
I expect they'll survive their legal problems just fine (Talc and Opioids), but I'd rather see some pessimism from inves...
Thank you for your insight. What do you think about JNJ? I think it's quite a compelling buy at this price point....
$ARTH Long Let me do a verbal interpretation of the above because ARTH is following the exact template of Closure. Clo...
$ARTH Long This is so interesting. Closure Medical---Marketing Agreements--Note Up Front licensing fees BEFORE regulat...
Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...
Hi Todd This should pick up a lot of momentum. Heck Norchi has been thinking of this commercialization moment si...
http://www.investor.jnj.com/janssen-phase-3-study-programme-of-esketamine-nasal-spray-in-patients-with-treatment-resista...
http://www.investor.jnj.com/janssen-phase-3-study-programme-of-esketamine-nasal-spray-in-patients-with-treatment-resista...
http://www.businessinsider.com/depression-medication-treatment-ketamine-2018-5 Not sure where you got the tease, but ...